CLINICAL TRIALS PROFILE FOR UROLOGIC G IN PLASTIC CONTAINER

All Clinical Trials for UROLOGIC G IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003930 ↗	Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	1999-09-01	RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy and surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients who have stage II or stage III bladder cancer that can be removed by surgery.
NCT00003930 ↗	Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer	Completed	Radiation Therapy Oncology Group	Phase 1/Phase 2	1999-09-01	RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy and surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients who have stage II or stage III bladder cancer that can be removed by surgery.
NCT00132301 ↗	Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma	Completed	Sanofi	Phase 3	2006-06-01	VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical prostatectomy but who are at high risk for relapse. The standard of care is surveillance, with the addition of androgen deprivation at the time of biochemical relapse. This study will assess the effect of adding early chemotherapy to the standard of care on progression free survival in Veterans at high risk for progression after prostatectomy.
NCT00132301 ↗	Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma	Completed	VA Office of Research and Development	Phase 3	2006-06-01	VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical prostatectomy but who are at high risk for relapse. The standard of care is surveillance, with the addition of androgen deprivation at the time of biochemical relapse. This study will assess the effect of adding early chemotherapy to the standard of care on progression free survival in Veterans at high risk for progression after prostatectomy.
NCT00138008 ↗	Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy	Completed	Ministry of Health, Labour and Welfare, Japan	Phase 3	2004-05-01	The purpose of this study is to evaluate radiotherapy followed by endocrine therapy in comparison with endocrine therapy alone for PSA failure after radical prostatectomy.
NCT00138008 ↗	Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy	Completed	Haruhiko Fukuda	Phase 3	2004-05-01	The purpose of this study is to evaluate radiotherapy followed by endocrine therapy in comparison with endocrine therapy alone for PSA failure after radical prostatectomy.
NCT00148083 ↗	Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia	Completed	Janssen, LP	Phase 3	2005-09-01	The specific aim of this study is to determine whether the new, long-acting, form of risperidone, Risperdal Consta, improves the ability of schizophrenia patients to benefit from skills training. The hypothesis guiding this study is that Risperdal Consta, by improving verbal memory, will improve the ability to benefit from skills training interventions among schizophrenia patients. The primary objective of this study is to compare patients on Risperdal Consta to patients on other atypical antipsychotic medications in terms of their ability to benefit from skills training interventions. A secondary objective of this study is to determine whether patients taking Risperdal Consta improve in other areas of cognitive functioning and social functioning.

Clinical Trial Conditions for UROLOGIC G IN PLASTIC CONTAINER

Condition Name

Condition Name for UROLOGIC G IN PLASTIC CONTAINER
Intervention	Trials
Prostate Cancer	9
Bladder Cancer	6
Pain, Postoperative	6
Urologic Diseases	4

Condition MeSH

Condition MeSH for UROLOGIC G IN PLASTIC CONTAINER
Intervention	Trials
Pain, Postoperative	14
Urinary Bladder Neoplasms	10
Syndrome	7
Prostatic Neoplasms	7

Clinical Trial Locations for UROLOGIC G IN PLASTIC CONTAINER

Trials by Country

Trials by Country for UROLOGIC G IN PLASTIC CONTAINER
Location	Trials
United States	215
Japan	25
Canada	19
Korea, Republic of	8
Egypt	3

Trials by US State

Trials by US State for UROLOGIC G IN PLASTIC CONTAINER
Location	Trials
New York	14
California	13
Michigan	10
Texas	10
Maryland	9

Clinical Trial Progress for UROLOGIC G IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for UROLOGIC G IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Phase 4	45
Phase 3	18
Phase 2	15

Clinical Trial Status

Clinical Trial Status for UROLOGIC G IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Completed	52
Recruiting	21
Not yet recruiting	17

Clinical Trial Sponsors for UROLOGIC G IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for UROLOGIC G IN PLASTIC CONTAINER
Sponsor	Trials
National Cancer Institute (NCI)	4
University of Texas Southwestern Medical Center	4
Yonsei University	4

Sponsor Type

Sponsor Type for UROLOGIC G IN PLASTIC CONTAINER
Sponsor	Trials
Other	154
Industry	26
NIH	6